We are live on ! Find out more
ARRY icon

Array Biopharma
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

129 hedge funds and large institutions have $545M invested in Array Biopharma in 2014 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 41 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

74% more capital inflows, than outflows

Capital inflows: $57.7M | Capital outflows: $33.1M

67% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 12

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

6% more funds holding

Funds holding: 122 → 129 (+7)

3.59% more ownership

Funds ownership: 67.27% → 70.86% (+3.6%)

12% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 41

60% less call options, than puts

Call options by funds: $1.42M | Put options by funds: $3.55M

Holders
129
Holders Change
+7
Holders Change %
+5.74%
% of All Funds
3.7%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.14%
New
20
Increased
36
Reduced
41
Closed
12
Calls
$1.42M
Puts
$3.55M
Net Calls
-$2.13M
Net Calls Change
+$1.05M

ARRY Hedge Fund Activity: Q2 2014 in Review

129 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma (ARRY) for Q2 2014, worth a combined $545M — up 2.2% from $533M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new ARRY positions and 12 closed out — a net gain of 8 holders — while 36 added to existing stakes and 41 trimmed.

The largest buyer was BVF Inc, adding an estimated $25.8M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $9.7M sold.

  • 129 institutional investors held Array Biopharma (ARRY) as of Q2 2014, up from 122 in Q1 2014.
  • Funds reported $545M of Array Biopharma stock for Q2 2014, up 2.2% quarter-over-quarter.
  • 20 funds opened new Array Biopharma positions in Q2 2014 and 12 closed out, a net change of +8 holders.
  • The largest Array Biopharma buyer in Q2 2014 was BVF Inc, an estimated $25.8M added.
  • The largest Array Biopharma seller in Q2 2014 was Balyasny Asset Management, an estimated $9.7M sold.

Based on aggregated 13F filings for Q2 2014.